» Articles » PMID: 38001576

Nidogen-1/NID1 Function and Regulation During Progression and Metastasis of Colorectal Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Nov 25
PMID 38001576
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously shown that the extracellular matrix and basement membrane protein Nidogen1 (NID1) is secreted by more malignant, mesenchymal-like CRC cells and induces the epithelial-mesenchymal transition (EMT) and promotes the migration and invasion of less malignant, epithelial-like CRC cells. Here, we performed a comprehensive bioinformatics analysis of multiple datasets derived from CRC patients and showed that elevated expression of and the genes , , and which encode NID1 receptors, is associated with poor prognosis and advanced tumor stage. Accordingly, the expression of , , , and was associated with an EMT signature, which included SNAIL/SNAI1, an EMT-inducing transcription factor. In CRC cells, ectopic SNAIL expression induced NID1 and SNAIL occupancy was detected at an E-box upstream of the transcription start site. Therefore, represents a direct target of SNAIL. Ectopic expression of NID1 or treatment with NID1-containing medium endowed non-metastatic CRC cells with the capacity to form lung metastases after xenotransplantation into mice. Suppression of the NID1 receptor ITGAV decreased cell viability, particularly in CMS/consensus molecular subtype 4 CRC cells. Taken together, our results show that is a direct target of EMT-TF SNAIL and is associated with and promotes CRC progression and metastasis. Furthermore, the NID1 receptor ITGAV represents a candidate therapeutic target in CMS4 colorectal tumors.

Citing Articles

NID1 promotes laryngeal cancer stemness via activating WNT pathway.

Liu W, Wu J, Lai Y, Zhang S, Yang A, Li Y Biol Direct. 2024; 19(1):115.

PMID: 39538332 PMC: 11558908. DOI: 10.1186/s13062-024-00548-0.


Identification of HSPG2 as a bladder pro-tumor protein through NID1/AKT signaling.

Li C, Luo P, Guo F, Jia X, Shen M, Zhang T Cancer Cell Int. 2024; 24(1):345.

PMID: 39438949 PMC: 11515648. DOI: 10.1186/s12935-024-03527-7.


Combined High-Throughput Proteomics and Random Forest Machine-Learning Approach Differentiates and Classifies Metabolic, Immune, Signaling and ECM Intra-Tumor Heterogeneity of Colorectal Cancer.

Contini C, Manconi B, Olianas A, Guadalupi G, Schirru A, Zorcolo L Cells. 2024; 13(16.

PMID: 39195201 PMC: 11352245. DOI: 10.3390/cells13161311.

References
1.
Cooper J, Giancotti F . Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019; 35(3):347-367. PMC: 6684107. DOI: 10.1016/j.ccell.2019.01.007. View

2.
Dong L, Hsieh J, CHUNG A . Two distinct cell attachment sites in entactin are revealed by amino acid substitutions and deletion of the RGD sequence in the cysteine-rich epidermal growth factor repeat 2. J Biol Chem. 1995; 270(26):15838-43. DOI: 10.1074/jbc.270.26.15838. View

3.
Elez E, Kocakova I, Hohler T, Martens U, Bokemeyer C, Van Cutsem E . Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2014; 26(1):132-140. DOI: 10.1093/annonc/mdu474. View

4.
Mori S, Wu C, Yamaji S, Saegusa J, Shi B, Ma Z . Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. J Biol Chem. 2008; 283(26):18066-75. PMC: 2440593. DOI: 10.1074/jbc.M801213200. View

5.
Hamidi H, Ivaska J . Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018; 18(9):533-548. PMC: 6629548. DOI: 10.1038/s41568-018-0038-z. View